Chiral Technologies, Inc. Acquires Arbor Biosciences – Increasing Their Portfolio for the Biopharma Industry
Product News Jan 16, 2019
Chiral Technologies, Inc. part of DAICEL CORPORATION, the global market leader in enantioselective chromatography, is pleased to announce the acquisition of Arbor Biosciences of Ann Arbor, MI.
Arbor Biosciences (formerly MYcroarray), founded in 2006 by University of Michigan Prof. Erdogan Gulari and Dr. Jean-Marie Rouillard, has evolved over the years from producing custom DNA microarrays to generating oligonucleotide pools using its proprietary massively parallel DNA synthesis technology. The primary growth driver is their myBaits targeted sequencing panels, both custom and catalog offerings, which are complemented by the services division to provide an end-to-end solution for their clients. Recently they have expanded into synthetic biology with a cell-free expression system using linear DNA as template for rapid protein expression.
“As we diversify our product portfolio to serve the needs of biopharma, Arbor Biosciences delivers the molecular biology foundation to fuel that growth” stated Joseph Barendt, Ph.D., President of Chiral Technologies, Inc.
“This is a very exciting time as we are moving Arbor Biosciences to the next level” stated Jean-Marie Rouillard, CSO and co-founder at Arbor Biosciences “The additional investments by DAICEL/Chiral will help accelerate our growth and deliver innovative, cost-effective solutions to our clients in the biotechnology and life sciences markets faster than previously planned. It will also open up access to new markets.”
Arbor Biosciences will continue to operate at its current location in Ann Arbor, MI as a wholly owned subsidiary of Daicel Corporation and managed by Chiral Technologies, Inc. The entire Arbor Biosciences team will remain in place, including co-founders Gulari and Rouillard.